JG
RARX

Jefferies Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Jefferies Group’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,000
Closed -$448K – 3032
2019
Q1 		$448K Buy
+20,000
New +$430K ﹤0.01% 1641

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Jefferies Group's RARX Position: Q2 2019 in Review

Jefferies Group sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2019, closing a stake of 20,000 shares — an estimated $448K sold.

Jefferies Group first reported a position in RARX in Q1 2019 and held it in 1 quarter. The position peaked at $448K in Q1 2019. 118 funds tracked by Wall St. Rank hold RARX as of Q2 2019.

  • Jefferies Group reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Jefferies Group sold 20,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $448K.
  • Jefferies Group first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Jefferies Group's Ra Pharmaceuticals, Inc. Common Stock position peaked at $448K in Q1 2019.
  • 118 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Jefferies Group's 13F filing for Q2 2019, filed 14 Aug 2019.